These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8060750)

  • 21. Analysis of the structure and expression of the c-myc oncogene in cervical tumor and in cervical tumor-derived cell lines.
    Choo KB; Chong KY; Chou HF; Liew LN; Liou CC
    Biochem Biophys Res Commun; 1989 Jan; 158(1):334-40. PubMed ID: 2463837
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Gain and overexpression of the oncostatin M receptor occur frequently in cervical squamous cell carcinoma and are associated with adverse clinical outcome.
    Ng G; Winder D; Muralidhar B; Gooding E; Roberts I; Pett M; Mukherjee G; Huang J; Coleman N
    J Pathol; 2007 Jul; 212(3):325-34. PubMed ID: 17516585
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and differential expression of novel human cervical cancer oncogene HCCR-2 in human cancers and its involvement in p53 stabilization.
    Ko J; Lee YH; Hwang SY; Lee YS; Shin SM; Hwang JH; Kim J; Kim YW; Jang SW; Ryoo ZY; Kim IK; Namkoong SE; Kim JW
    Oncogene; 2003 Jul; 22(30):4679-89. PubMed ID: 12879013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. C14ORF166 overexpression is associated with pelvic lymph node metastasis and poor prognosis in uterine cervical cancer.
    Zhang W; Ou J; Lei F; Hou T; Wu S; Niu C; Xu L; Zhang Y
    Tumour Biol; 2016 Jan; 37(1):369-79. PubMed ID: 26219895
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [RNA interference: biogenesis molecular mechanisms and its applications in cervical cancer].
    Peralta-Zaragoza O; Bermúdez-Morales VH; Madrid-Marina V
    Rev Invest Clin; 2010; 62(1):63-80. PubMed ID: 20415061
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gene expression changes in residual advanced cervical cancer after radiotherapy: indicators of poor prognosis and radioresistance?
    Fu ZC; Wang FM; Cai JM
    Med Sci Monit; 2015 May; 21():1276-87. PubMed ID: 25940978
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Association between activated K-ras and c-erbB-2 oncogenes with "high-risk" and "low-risk" human papilloma virus types in preinvasive cervical lesions.
    Mourón SA; Abba MC; Güerci A; Gómez MA; Dulout FN; Golijow CD
    Mutat Res; 2000 Aug; 469(1):127-34. PubMed ID: 10946249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and mutation of H-ras in uterine cervical cancer.
    Lee JH; Lee SK; Yang MH; Ahmed MM; Mohiuddin M; Lee EY
    Gynecol Oncol; 1996 Jul; 62(1):49-54. PubMed ID: 8690291
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New markers for cervical dysplasia to visualise the genomic chaos created by aberrant oncogenic papillomavirus infections.
    von Knebel Doeberitz M
    Eur J Cancer; 2002 Nov; 38(17):2229-42. PubMed ID: 12441259
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic significance of the overexpression of c-erbB-2 protein in adenocarcinoma of the uterine cervix.
    Kihana T; Tsuda H; Teshima S; Nomoto K; Tsugane S; Sonoda T; Matsuura S; Hirohashi S
    Cancer; 1994 Jan; 73(1):148-53. PubMed ID: 7506116
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Flow cytometric quantitation of DNA and c-myc oncoprotein in archival biopsies of uterine cervix neoplasia.
    Hendy-Ibbs P; Cox H; Evan GI; Watson JV
    Br J Cancer; 1987 Mar; 55(3):275-82. PubMed ID: 3552016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation of cervical carcinoma c-erb B-2 oncogene with cell proliferation parameters in patients treated with radiation therapy for cervical carcinoma.
    Nakano T; Oka K; Ishikawa A; Morita S
    Cancer; 1997 Feb; 79(3):513-20. PubMed ID: 9028362
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Papillomavirus and c-myc antigen expression in normal and neoplastic cervical epithelium.
    Hughes RG; Neill WA; Norval M
    J Clin Pathol; 1989 Jan; 42(1):46-51. PubMed ID: 2537854
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nuclear proto-oncogene products transactivate the human papillomavirus type 16 promoter.
    Nürnberg W; Artuc M; Vorbrueggen G; Kalkbrenner F; Moelling K; Czarnetzki BM; Schadendorf D
    Br J Cancer; 1995 May; 71(5):1018-24. PubMed ID: 7734293
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chlamydia trachomatis modulates expression of tumor suppressor gene caveolin-1 and oncogene C-myc in the transformation zone of non-neoplastic cervical tissue.
    Schlott T; Eiffert H; Bohne W; Landgrebe J; Brunner E; Spielbauer B; Knight B
    Gynecol Oncol; 2005 Sep; 98(3):409-19. PubMed ID: 16005053
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New molecular tools for efficient screening of cervical cancer.
    von Knebel Doeberitz M
    Dis Markers; 2001; 17(3):123-8. PubMed ID: 11790875
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular profiling of cervical neoplasia.
    Martin CM; Astbury K; O'Leary JJ
    Expert Rev Mol Diagn; 2006 Mar; 6(2):217-29. PubMed ID: 16512781
    [TBL] [Abstract][Full Text] [Related]  

  • 38. p53 gene alterations and human papillomavirus type 16 infection in early stages of cervical carcinoma in Serbia.
    Malisic E; Jankovic R; Majkic M; Dobricic J; Radulovic S
    J BUON; 2008; 13(4):525-32. PubMed ID: 19145674
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Oncogenes and growth factors in thyroid carcinogenesis.
    Frauman AG; Moses AC
    Endocrinol Metab Clin North Am; 1990 Sep; 19(3):479-93. PubMed ID: 2175702
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The c-myc activation in cervical carcinomas and HPV 16 infections.
    Abba MC; Laguens RM; Dulout FN; Golijow CD
    Mutat Res; 2004 Feb; 557(2):151-8. PubMed ID: 14729369
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.